October 1, 2018 / 7:28 AM / 2 months ago

BRIEF-Innate Pharma Publishes Phase 1 IPH4102 Results

1 Min Read

Oct 1(Reuters) - Innate Pharma:

* REPORTED ON SATURDAY IPH4102 PHASE 1 RESULTS IN ADVANCED CUTEANOUS T CELL LYMPHOMA

* RESULTS SHOW HIGH RESPONSE RATE AND LONG PROGRESSION-FREE SURVIVAL

Source text for Eikon:

Further company coverage: (Gdynia Newsroom)

Our Standards:The Thomson Reuters Trust Principles.

0 : 0

narrow-browser-and-phone
medium-browser-and-portrait-tablet
landscape-tablet
medium-wide-browser
wide-browser-and-larger
medium-browser-and-landscape-tablet
medium-wide-browser-and-larger
above-phone
portrait-tablet-and-above
above-portrait-tablet
landscape-tablet-and-above
landscape-tablet-and-medium-wide-browser
portrait-tablet-and-below
landscape-tablet-and-below